• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

New Study Boosts Solriamfetol’s Momentum

October 29, 2020 by admin

Jazz Pharmaceuticals touted the benefits of Solriamfetol via a new study at the recently concluded virtual edition of the CHEST Annual Meeting. An post conference wrap-up highlights a study of the compound treats excessive daytime sleepiness (EDS) due to obstructive sleep apnea (OSA).

The study titled “

LONG-TERM EFFECTS OF SOLRIAMFETOL ON EXCESSIVE DAYTIME SLEEPINESS AND FUNCTIONAL OUTCOMES IN PARTICIPANTS WITH OSA “presented at the CHEST Annual Meeting 2020 evaluated Solriamfetol’s efficacy on functional outcomes in a long-term study’s randomized withdrawal (RW) phase.

CLICK HERE FOR ABSTRACT

“The present analysis included patients with OSA who took part in a previous trial of solriamfetol,”. “Open-label solriamfetol treatment was performed for about six months, at which time a subgroup of patients was randomized for the two-week RW phase to receive either placebo (n=101) or solriamfetol (n=99).” 

Assessments included change in Functional Outcomes of Sleep Questionnaire (FOSQ-10) total score and Epworth Sleepiness Scale (ESS) score from initiation to conclusion, as well as the percentage of patients who were reported as worse per the Patient Global Impression of Change (PGI-C) and Clinician Global Impression of Change (CGI-C). D’Onofrio explains that, “By the end of the RW phase, placebo patients experienced worsening FOSQ-10 total scores (least squares [LS] mean change, –2.4), while the solriamfetol group maintained their scores (LS mean change, –0.8; LS mean difference, 1.6; 95% confidence interval [CI], 0.80-2.37; P=0.0001).” 

Researchers concluded: “These data support long-term maintenance of efficacy of solriamfetol for treating EDS and improving daily functioning in patients with OSA.”   

Source: American College of Chest Physicians

 

Filed Under: Blog, News

Primary Sidebar

More to See

Snoring, American Sleep and Breathing Academy and the NY Times

August 23, 2022 By admin

Jazz Pharma Presents 17 New Posters for SLEEP 2022

June 6, 2022 By admin

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • SUPPORT AND PROMOTE DENTAL SLEEP MEDICINE IN 2023!
  • Snoring, American Sleep and Breathing Academy and the NY Times
  • Jazz Pharma Presents 17 New Posters for SLEEP 2022
  • AJMC Hypes SLEEP 2022
  • Avadel Pharmaceuticals’ Stock Falls

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2023 · Sleep Diagnosis and Therapy